Korean J Fam Med.  2012 Sep;33(5):253-261. 10.4082/kjfm.2012.33.5.253.

Factors of Compliance in Patients with Hypercholesterolemia Using Rosuvastatin in Primary Care

• Kim HY
• Lee JA
• Kim YS
• Sunwoo S
• Oh HJ
• Kim CS
• Yum K
• Choi C
• Jeong YS
• Song SW
• Kim DH
• Kim YS

• KMID: 2304240
• DOI: http://doi.org/10.4082/kjfm.2012.33.5.253

Abstract

BACKGROUND
In order to evaluate the factors of compliance with a lipid lowering therapy, a prospective observational study of patients with hypercholesterolemia using rosuvastatin was carried out.
METHODS
A total of 2,607 patients who were newly prescribed rosuvastatin were enrolled from 32 family physicians in Korea from March 2009 to December 2009. Of them, 301 patients were excluded due to incomplete data or follow-up compliance data. The patients were regularly observed to ascertain the compliance associated with rosuvastatin at intervals of 12 and 24 weeks. We collected risk factors for the compliance using a structured questionnaire. The criteria for evaluating compliance are to measure clinic attendance, to assess the continuity of therapy, and to calculate the percentage of doses taken.
RESULTS
Among a total of 2,306 patients, the degree of compliance was 54.1%. According to logistic regression analysis, the factors for compliance with the lipid lowering drug included old age (odds ratio [OR], 2.68; 95% confidence interval [CI], 2.09 to 3.45), frequent exercise (OR, 1.76; 95% CI, 1.43 to 2.18), previous statin therapy (OR, 4.02; 95% CI, 3.22 to 5.01), hypertension (OR, 1.80; 95% CI, 1.48 to 2.19), diabetes mellitus (OR, 2.20; 95% CI, 1.69 to 2.87), concomitant medication (OR, 2.28; 95% CI, 1.88 to 2.77), and high coronary heart disease (CHD) risk category (OR, 1.82; 95% CI, 1.39 to 2.38). The compliance decreased with high low density lipoprotein cholesterol levels (OR, 0.20; 95% CI, 0.16 to 0.26).
CONCLUSION
The compliance of patients using rosuvastatin was 54.1% in primary care. The factors related to higher compliance were old age, regular exercise, previous statin therapy, concomitant medication, presence of hypertension or diabetes, and higher CHD risk level.

Keyword

Hypercholesterolemia; Compliance; Rosuvastatin; Lipid Lowering Therapy

MeSH Terms

Cholesterol
Cholesterol, LDL
Compliance
Coronary Disease
Diabetes Mellitus
Fluorobenzenes
Follow-Up Studies
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypercholesterolemia
Hypertension
Korea
Lipoproteins
Logistic Models
Physicians, Family
Primary Health Care
Prospective Studies
Pyrimidines
Risk Factors
Sulfonamides
Rosuvastatin Calcium
Surveys and Questionnaires
Cholesterol
Cholesterol, LDL
Fluorobenzenes
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lipoproteins
Pyrimidines
Sulfonamides